Novavax vaccine recommended for approval for EU teenagers

Shares in US-based vaccine producer Novovax increased in value by 13.9% on Thursday in US trading after the Committee for Medicinal Products for Human Use, the CHMP, recommended the vaccine be used in children aged 12-17.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Moderna on booster race: May the best data win
For subscribers
EMA begins review of Novavax's Covid-19 vaccine
For subscribers
Epidemiologist calls Pfizer's corona pill a "game changer"
For subscribers